I am very curious if any MPNérs are using Metaformin and what effects they are experiencing on their MPN...
See: In this study we found an inverse association between MT use and risk of MPNs indicating a potential protective effect of MT on the development of MPNs. The protective effect was most pronounced for long-term use, older age (≥60 years) and for polycythemia vera and essential thrombocythemia. Whether this effect is causal should be determined interventional studies.
I have heard of metformin possibly helping mpn’s. Somebody mentioned it on this site at least a year ago. When I mentioned it to my haematologist she didn’t seem to be aware of it. Hopefully someone on here might be able to update us if they take metformin. Thanks for the post
While I haven't heard of that specifically, I am very interested in it, so thank you for sharing it!
I have a mild FMHx of DMII, so I would be willing to start metformin prophylactically, especially if some beneficial effect could accrue re: my PV.
I do know that there are folks out in the world taking it[along with statins and/or ACE-inhibitors] for the purpose of life/longevity extension, with the premise that they all have anti-inflammatory/anti-neoplastic properties.
In fact, I have also seen one study regarding ACE-I's for kidney-protection in MPN's.
Beneficial effect of ACE inhibitors on kidney function in polycythemia vera:
"Since statins may enhance the efficacy of ruxolitinib79 and rIFNα,80 triple therapy of rIFNα + ruxolitinib + statin may be a highly effective triplet, but obviously requires evaluation in future trials.13,74 A recent study indicates hypoxia-inducible factor 1 (HIF-1) as a new therapeutic target in JAK2V617F-positive MPNs, demonstrating the potential of the peptide antibiotic, echinomycin, alone and in combination with ruxolitinib, to selectively target JAK2V617F-positive cells inducing apoptosis and cell cycle arrest.81 In this context, it may be interesting to combine a HIF-1-inhibitor and JAK1-2 inhibitor with rIFNα, which might further enhance the synergistic effects of combining ruxolitinib and rIFNα.
Combination with statins
Statins have been suggested as potentially useful enhancers of rIFNα in treating MPNs, owing to their antiproliferative, antiangiogenic, proapoptotic, and anti-inflammatory attributes.82,83 A recent study showed that PV patients who are treated with statins require fewer phlebotomies than those who are not.84 Although the underlying mechanisms are elusive, a statin-induced lowering of inflammation in JAK-STAT signaling is a possible explanation.82,83 In this context, we note that low-density lipoproteins (LDLs) amplify cytokine-signaling in chronic lymphocytic leukemia cells.85 Thus, future studies should address whether LDLs enhance proliferation of MPN cells in response to inflammatory signals. Because patients with MPNs have an increased risk of second cancers59–63 and because statins have been shown to reduce cancer-associated mortality by 15%,86 their role in the treatment of MPNs is currently under investigation."
in here:
New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
COVID-19 & MYELOPROLIFERATIVE NEOPLASMS: FAQs & UPDATES from ASH_30.03.20
Anti inflammatory diet 
HU Resistance/Intolerance Prognostic from Dr Gotlib
